Abstract
I read with interest the editorial by Dr. Roy Fleischmann on the limitations of the multibiomarker disease activity test (MBDA) in the management of rheumatoid arthritis (RA)1. He provides a comprehensive review of some of the key studies of MBDA in clinical trials and concludes that the “MBDA has not met the test of being a biomarker that can predict who will or will not respond to a specific therapy, who will or will not be able to taper or stop therapy or who will or will not have radiographic progression.”